Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(02): 143
DOI: 10.4103/2278-330X.130480
Letters to Editor

NK cell therapy for end‑stage cancerous patient: A case study

Junichi Masuyama
New City Osaki Clinic, Tokyo, Japan
,
Kamon Chaiyasit
Vitallife Wellness Center at Bumrungrad International, BKK, Thailand
,
Wanviput Sanphasitvong
Vitallife Wellness Center at Bumrungrad International, BKK, Thailand
,
Viroj Wiwanitkit
Hainan Medical University, China
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, et al. Cell therapy: Achievements and perspectives. Haematologica 1999;84:1110-49.
  • 2 Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother 2014;63:21-8.
  • 3 Campbell KS, Hasegawa J. Natural killer cell biology: An update and future directions. J Allergy Clin Immunol 2013;132:536-44.
  • 4 Ejiri Y, Ohara M, Suzuki T, Kasukawa R. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells. Fukushima J Med Sci 1997;43:61-73.
  • 5 Yannelli JR. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods 1991;139:1-16.